Have your own idea? Try our Stock Screener
Chinese (SSE) Life Sciences Industry Analysis
UpdatedMay 30, 2025
DataAggregated Company Financials
Companies26
- 7D3.4%
- 3M-1.7%
- 1Y29.5%
- YTD13.5%
Last week, the Life Sciences industry hasn't moved much but Beijing Sun-Novo Pharmaceutical Research is up 8.7% in that time. The past year has been better, since the industry has gained 25% in that time. As for the next few years, earnings are expected to grow by 30% per annum.
Industry Valuation and Performance
Has the Chinese Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 30 May 2025 | CN¥413.2b | CN¥89.1b | CN¥15.3b | 44.9x | 27x | 4.6x |
| Sun, 27 Apr 2025 | CN¥379.9b | CN¥88.2b | CN¥13.6b | 39.6x | 28x | 4.3x |
| Tue, 25 Mar 2025 | CN¥437.0b | CN¥88.4b | CN¥14.6b | 41.7x | 30x | 4.9x |
| Thu, 20 Feb 2025 | CN¥412.6b | CN¥88.1b | CN¥11.2b | 41.8x | 36.7x | 4.7x |
| Sat, 18 Jan 2025 | CN¥352.0b | CN¥88.1b | CN¥11.2b | 37x | 31.3x | 4x |
| Mon, 16 Dec 2024 | CN¥388.6b | CN¥87.8b | CN¥11.2b | 40.1x | 34.7x | 4.4x |
| Wed, 13 Nov 2024 | CN¥411.9b | CN¥87.8b | CN¥11.2b | 44.7x | 36.8x | 4.7x |
| Fri, 11 Oct 2024 | CN¥388.5b | CN¥88.2b | CN¥12.4b | 35.2x | 31.4x | 4.4x |
| Sun, 08 Sep 2024 | CN¥274.1b | CN¥87.1b | CN¥12.3b | 27.9x | 22.3x | 3.1x |
| Tue, 06 Aug 2024 | CN¥299.1b | CN¥87.6b | CN¥12.6b | 28.6x | 23.8x | 3.4x |
| Thu, 04 Jul 2024 | CN¥274.4b | CN¥88.3b | CN¥13.4b | 24.1x | 20.5x | 3.1x |
| Sat, 01 Jun 2024 | CN¥309.0b | CN¥88.3b | CN¥13.4b | 27.5x | 23.1x | 3.5x |
| Mon, 29 Apr 2024 | CN¥318.6b | CN¥90.2b | CN¥14.4b | 30.4x | 22.1x | 3.5x |
| Wed, 27 Mar 2024 | CN¥340.0b | CN¥90.4b | CN¥15.6b | 31.7x | 21.8x | 3.8x |
| Fri, 23 Feb 2024 | CN¥358.3b | CN¥91.1b | CN¥16.1b | 31.8x | 22.3x | 3.9x |
| Sun, 21 Jan 2024 | CN¥452.3b | CN¥91.1b | CN¥16.1b | 35.4x | 28.1x | 5x |
| Tue, 19 Dec 2023 | CN¥475.7b | CN¥91.1b | CN¥16.1b | 37.4x | 29.6x | 5.2x |
| Thu, 16 Nov 2023 | CN¥558.5b | CN¥91.1b | CN¥16.1b | 40.9x | 34.7x | 6.1x |
| Sat, 14 Oct 2023 | CN¥548.6b | CN¥92.0b | CN¥18.3b | 36.2x | 29.9x | 6x |
| Mon, 11 Sep 2023 | CN¥470.0b | CN¥91.9b | CN¥18.3b | 32.3x | 25.7x | 5.1x |
| Wed, 09 Aug 2023 | CN¥480.5b | CN¥91.8b | CN¥18.5b | 34.8x | 26x | 5.2x |
| Fri, 07 Jul 2023 | CN¥452.7b | CN¥91.3b | CN¥18.5b | 34.5x | 24.5x | 5x |
| Sun, 04 Jun 2023 | CN¥499.9b | CN¥91.3b | CN¥18.5b | 38.6x | 27.1x | 5.5x |
| Tue, 02 May 2023 | CN¥514.4b | CN¥92.4b | CN¥19.0b | 43.1x | 27.1x | 5.6x |
| Thu, 30 Mar 2023 | CN¥585.4b | CN¥90.2b | CN¥19.9b | 49.1x | 29.5x | 6.5x |
| Sat, 25 Feb 2023 | CN¥612.5b | CN¥86.6b | CN¥20.8b | 53x | 29.4x | 7.1x |
| Mon, 23 Jan 2023 | CN¥713.5b | CN¥86.6b | CN¥20.8b | 60.6x | 34.3x | 8.2x |
| Wed, 21 Dec 2022 | CN¥554.0b | CN¥86.6b | CN¥20.8b | 46.7x | 26.6x | 6.4x |
| Fri, 18 Nov 2022 | CN¥645.0b | CN¥86.5b | CN¥20.8b | 56.3x | 31x | 7.5x |
| Sun, 16 Oct 2022 | CN¥585.2b | CN¥78.2b | CN¥16.9b | 48.8x | 34.6x | 7.5x |
| Tue, 13 Sep 2022 | CN¥614.4b | CN¥77.8b | CN¥17.0b | 49.6x | 36.1x | 7.9x |
| Thu, 11 Aug 2022 | CN¥623.1b | CN¥73.3b | CN¥17.1b | 67.7x | 36.4x | 8.5x |
| Sat, 09 Jul 2022 | CN¥748.9b | CN¥69.0b | CN¥15.2b | 75.5x | 49.3x | 10.9x |
| Mon, 06 Jun 2022 | CN¥577.0b | CN¥69.0b | CN¥15.2b | 55.6x | 38x | 8.4x |
Price to Earnings Ratio
38x
Current Industry PE
- Investors are pessimistic on the Chinese Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 26.2x which is lower than its 3-year average PE of 29.4x.
- The 3-year average PS ratio of 5.5x is higher than the industry's current PS ratio of 4.5x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have remained mostly flat over the last three years.
- Meanwhile revenues for these companies have grown 8.9% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | -0.074% | |
| Healthcare | 2.04% | |
| Life Sciences | 3.41% | |
| Clinical Research and Equipment | 3.41% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 603259 WuXi AppTec | CN¥64.70 | 3.0% +CN¥5.3b | 54.3% | PE14.2x | |
| 300347 Hangzhou Tigermed Consulting | CN¥47.82 | 6.1% +CN¥2.4b | -11.2% | PE121.9x | |
| 300759 Pharmaron Beijing | CN¥23.76 | 4.8% +CN¥1.9b | 13.8% | PE22.5x | |
| 603127 Joinn Laboratories(China)Co.Ltd | CN¥18.17 | 7.9% +CN¥975.4m | 19.7% | PE34.4x | |
| 688621 Beijing Sun-Novo Pharmaceutical Research | CN¥53.10 | 18.1% +CN¥890.6m | 7.7% | PE43.2x |